IGF-1, a hormone that CJC-1295 and ipamorelin increase, has a genuine and well-documented role in hair follicle biology. This stems from general dermatological studies. However, no studies have specifically tested CJC-1295 or ipamorelin for hair growth or loss in humans. Any claim in either direction—positive or negative—is therefore currently a likely extension of hair biology science rather than a directly confirmed effect of these two peptides.
Do CJC-1295 i ipamorelin hjælpe med hårvækst?
There is a well-founded, well-established scientific basis linking IGF-1 to hair follicle health. It is worth clarifying this explicitly before discussing what it does and does not mean specifically for CJC-1295 and ipamorelin. A 2025 scientific review, focusing on the role of IGF-1 in hair regeneration, described something interesting. IGF-1 is naturally produced by hair follicle dermal papilla cells – specialised cells at the base of each hair follicle. It plays a documented role in prolonging the active growth phase of the hair cycle, known as anagen. It also supports the formation of blood vessels around the follicle, helping to supply nutrients [1]. The same review noted that IGF-1 signalling is an important regulator of hair follicle growth and tissue repair. Reduced IGF-1 activity has been linked to conditions such as androgenetic alopecia. Dermal papilla cells from balding areas of the scalp have been shown to secrete measurably less IGF-1 than cells from non-balding areas [1].
Animal studies in the same literature provide additional support. Injecting IGF-1 directly into mouse skin increased hair follicle number and lengthened hair growth phase. This supports the biological plausibility of IGF-1’s link to hair growth at a mechanistic level [1]. However, it is important to be precise about what this evidence shows and does not show. These studies establish that IGF-1 itself plays a significant role in hair follicle biology. However, they largely come from animal studies, local or topical applications, and observational comparisons of human tissues. None of them involve CJC-1295 or ipamorelin. No study has tested whether raising IGF-1 systemically – throughout the body, via peptide injection – with these specific compounds elicits any measurable effect on human hair growth.
This distinction is important. A topically applied or directly injected growth factor acting on skin tissue is pharmacologically distinct from systemically circulating IGF-1 growth that follows growth hormone stimulation elsewhere in the body.
Do CJC-1295 and ipamorelin cause hair loss?
Just as there is no direct evidence that CJC-1295 or ipamorelin promote hair growth, there are also no published studies showing these compounds cause hair loss. In fact, existing science on hair and IGF-1 points in the opposite theoretical direction of the concern for hair loss. Reduced, not increased, IGF-1, has been linked to poorer hair follicle health in the dermatological literature discussed above [1]. However, one should approach anecdotal reports of hair loss circulating in online communities around these peptides with caution. Correlation in an individual's personal experience does not establish that the compound caused the specific outcome. This is especially true for something like hair loss, which has many common causes – genetics, stress, other medications, nutritional status – entirely unrelated to peptide use. These factors may coincide with peptide use purely by chance.
Since no controlled studies have tracked hair outcomes in individuals using CJC-1295 or ipamorelin, this article cannot confirm or deny a risk of hair loss. Claims in either direction found in informal online discussions should be treated as anecdotal, rather than scientifically established.
The connection between CJC-1295 and Ipamorelin with hair and IGF-1
The main scientific link connecting these peptides generally to the conversation about hair growth is indirect. It goes through the common hormone IGF-1. CJC-1295 and ipamorelin raise growth hormone, which in turn raises IGF-1 [2], [3]. It is independently known that IGF-1 plays a significant role in the hair growth cycle [1]. This creates a scientifically plausible hypothesis worth treating seriously as a hypothesis. Raising systemic IGF-1 could theoretically support hair follicle health. However, this remains exactly that: a hypothesis. It is built by combining two separate bodies of research – the hormonal effects of CJC-1295 and ipamorelin and the role of IGF-1 in hair biology. It is not a discovery demonstrated by any single study that has tested the actual compounds on actual hair outcomes.
It's also worth noting something about the supporting research itself. Most research on hair and IGF-1 involves either animal models, local or topical application of IGF-1 directly to the skin, or observations comparing tissue from balding versus non-balding areas. None of these are the same experimental setup as measuring whether systemic IGF-1 increases from growth hormone-releasing peptide injections would significantly alter hair growth in a living person over time.
Given this evidentiary gap, any „before and after” claims of hair growth attributed to CJC-1295 or ipamorelin circulating in marketing or anecdotal contexts are not supported by direct research. They should be treated with appropriate scepticism.
Limitations of current evidence
The link between hair and IGF-1 is rooted in genuine, peer-reviewed dermatological science. However, these studies were conducted independently of CJC-1295 and ipamorelin. They employed various research models – animal studies, topical administration to the skin, and observational tissue comparisons – rather than systemic peptide administration in humans.
No studies identified in the literature reviewed for this article have directly tested CJC-1295 or ipamorelin for hair growth or hair loss outcomes. This means that both potential benefit and potential harm remain unproven, theoretical possibilities rather than established facts.
Disclaimer
This content is for educational and informational purposes only and should not be construed as medical advice, diagnosis, or treatment recommendation. CJC-1295 and ipamorelin remain research chemicals and are not approved by the FDA or European Medicines Agency for any medical use, whether used individually or in combination. No published studies have directly tested these compounds for hair growth or hair loss outcomes in humans. The compounds described herein are based on separate studies on the role of IGF-1 in hair biology, not on direct studies of CJC-1295 or ipamorelin. Any individual experiencing hair loss should consult a dermatologist or healthcare professional to determine the underlying cause.
References
[1] Hsieh, W.-J., Qiu, W.-Y., Percec, I., & Chang, T.-M. (2025). Insulin-like growth factor 1 (IGF-1) in hair regeneration: Mechanistic pathways and therapeutic potential. Current Issues in Molecular Biology, 47(9), Article 773. https://doi.org/10.3390/cimb47090773
[2] Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
[3] Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modelling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402